Taken together, these results implicate the GR–LEDGF/p75 axis in PCa cell resistance to taxane therapy and are consistent with growing evidence demonstrating a role for these proteins in therapy resistance in various human cancer types. This evidence concerns the gene NR3C1 and cancer.